Evotec stock weak after half-year 2026 results confirm guidance cut

Evotec stock extends its weak performance after half-year 2026 figures showed a 19.2 percent revenue drop, deeper losses and a confirmed guidance cut while the shares trade close to their 52-week low.

Evotec SE (ISIN DE0005664809) stock remains under pressure on August 31, 2026, as investors digest weak half-year 2026 figures and a confirmed guidance cut while the shares trade close to their 52-week low around EUR 3.20.

Half-year 2026 shows steep revenue and EBITDA deterioration

A detailed analysis of Evotec's recently published half-year 2026 numbers highlights how the earnings picture has deteriorated. Per a German market commentary dated August 31, 2026, Evotec reported that revenue for the first six months of 2026 fell 19.2 percent to EUR 300.1 million compared with the same period of 2025, underscoring a significant slowdown in its business activity. The same report points out that adjusted EBITDA dropped from a slightly negative EUR -1.9 million in the prior-year half to a much deeper EUR -42.7 million in the first half of 2026, illustrating how profitability has moved further into loss territory.

The commentary notes that the weaker half-year data follow a guidance cut announced in July 2026 and that this reduced outlook has now been confirmed for the full year 2026. According to the article, management reiterated that the lowered forecast remains valid, meaning there is no near-term relief from a fundamental perspective. The report adds that Evotec has put a strong emphasis on liquidity and balance-sheet measures, mentioning a placed convertible bond of EUR 116.1 million and proceeds of around USD 100 million from a monetization of the company's Tubulis stake as part of its financing and strategic actions.

Segment trends and Horizon cost-savings program

Despite the overall weakness, the half-year breakdown shows notable differences between business segments. In the Discovery and Preclinical Development area, the same analysis highlights that net sales excluding strategic partnerships increased 28 percent year over year in the first half of 2026, suggesting that core discovery services continue to grow even as the consolidated group revenue declined. In contrast, other areas and the impact of partnership dynamics weighed on the top line.

The article also underlines that Evotec's biologics activities under the Just-Evotec Biologics banner are running at high capacity utilization with an expanded customer base. However, the associated revenue contributions are expected to show up mainly from the fourth quarter of 2026 onward, meaning that investors still have to wait several months before seeing these operational trends translate into reported numbers. At the same time, Evotec is rolling out its Horizon program, which is targeted to deliver EUR 75 million in operating cost savings by the end of 2027, offering a medium-term lever to stabilize margins if execution goes as planned.

Share price trades close to 52-week low

The weak fundamental backdrop is mirrored in Evotec's share price performance. The cited German commentary explains that since the start of 2026 the stock has lost 38 percent of its value, and over a twelve-month period the decline reaches 45 percent. It further specifies that the shares previously reached a 52-week high of EUR 7.75 on November 5, 2025, and have since retreated significantly, with the current level marking a 57 percent drop from that high. In contrast, the distance to the most recent 52-week low of EUR 3.19, set on July 14, 2026, is only 5.5 percent, which illustrates how closely the shares are hovering around their lower reference band.

A same-day market overview published on August 30, 2026, shows Evotec shares closing at EUR 3.37 at the end of that trading session, just 5.5 percent above the 52-week low of EUR 3.19 recorded in July 2026. This overview also reports a market capitalization of EUR 597.29 million as of August 30, 2026, underscoring how the company's equity valuation has shrunk compared with earlier stages in the cycle.

Intraday data from August 31, 2026 show that Evotec shares continued to trade weakly in Xetra trading. One snapshot at 12:28 p.m. local time indicated a price of EUR 3.24, down 3.2 percent on the day, while a later update at 4:28 p.m. local time showed the stock at EUR 3.25 with losses of 3.0 percent versus the previous close. The midday price update and the afternoon price update show that the stock remained under pressure during the session, moving between EUR 3.22 and EUR 3.25, which keeps it within a narrow corridor close to the 52-week low.

Valuation, investor sentiment and consensus context

For investors, the combination of sharply lower revenue, a swing to a more negative adjusted EBITDA and a stock price near its 52-week low raises questions about valuation and sentiment. The market commentary stresses that the loss of 38 percent since the beginning of 2026 and a 45 percent decline over twelve months signal persistent uncertainty. The distance between the EUR 7.75 high and the current EUR 3.20-range trading band points to a significant reassessment of Evotec's prospects by the market.

At the same time, the company has responded with tactical and strategic measures. The placed convertible bond of EUR 116.1 million and the monetization of the Tubulis holding, which yielded around USD 100 million, have bolstered liquidity. The same report describes these steps in the context of funding the Horizon program and other operational initiatives, indicating that management is trying to buy time and financial flexibility. The liquidity theme is reinforced by the August 30, 2026 overview, which references a total liquidity position in the mid-hundreds of millions of euros and views this as a stabilizing factor alongside cost-cutting plans.

The broader market environment in August 2026 has also been challenging, with financial markets facing elevated commodity prices and higher sovereign yields, adding pressure on growth companies and those with negative earnings. A daily financial markets report dated August 31, 2026 notes that inflation concerns and restrictive central-bank rhetoric have weighed on risk assets in recent weeks. In such an environment, a stock that combines declining revenue, negative EBITDA and a still unfolding restructuring story typically faces a cautious stance from many market participants.

While no detailed analyst consensus for Evotec's earnings or target price appears in the available data set for this call, the dynamics described in the half-year commentary suggest that expectations have been reset lower following the July guidance cut. The confirmation of the reduced forecast in the half-year 2026 communication signals that management does not yet see enough evidence to raise its outlook, which can cap near-term upside until the Discovery segment growth and Just-Evotec Biologics capacity translate into visibly higher group revenue and improved EBITDA from late 2026 onward.

Discovery services as a core business pillar

Evotec's business model centers on partnering with pharmaceutical and biotechnology companies to discover and develop new drug candidates, and the Discovery and Preclinical Development segment plays a key role in that strategy. As the half-year 2026 breakdown highlights, net sales in this segment excluding strategic partnerships rose 28 percent year over year, demonstrating that underlying demand for discovery services remains robust despite the group's overall revenue decline. This growth reflects a diversified client base and ongoing contracts across different therapeutic areas.

A representative example of Evotec's product offering is its integrated discovery platform, which combines early-stage biology, medicinal chemistry and translational research capabilities for partners. Through this kind of platform, Evotec supports clients from target identification to preclinical proof-of-concept, aiming to shorten development timelines and improve hit discovery and optimization. The high capacity utilization reported for Just-Evotec Biologics shows that similar integrated concepts are being applied in biologics manufacturing and development, with a focus on flexible capacity and tailored solutions.

Evotec stock price as of the latest session

Evotec shares trade primarily on the Xetra segment of the Frankfurt Stock Exchange in euros. According to the market overview anchored on August 30, 2026, the stock closed that session at EUR 3.37, with a market capitalization of EUR 597.29 million as of the same date. Intraday data from August 31, 2026 show prices in a very similar band, between EUR 3.22 and EUR 3.25 during the day, with percentage losses of around 3 percent versus the prior close. For retail investors, this means Evotec stock currently trades just a few percentage points above its 52-week low of EUR 3.19, signaling a market that continues to price in significant execution and earnings risk while awaiting clearer signs that the Horizon program and segment growth can turn the earnings trajectory.

Read more on Evotec stock

Further corporate news coverage on Evotec stock offers additional context on liquidity and valuation trends.

Fact box

Company: Evotec SE

ISIN: DE0005664809

Ticker: EVT

Exchange: Xetra (Frankfurt Stock Exchange)

Price (as of August 30, 2026, 4:00 p.m. local time): EUR 3.37

Market cap: EUR 597.29 million (as of August 30, 2026)

Sector / Industry: Healthcare / Biotechnology and drug discovery services

Index membership: MDAX